<DOC>
	<DOCNO>NCT00003369</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist tirapazamine plus cisplatin treating patient metastatic , recurrent , refractory cervical cancer .</brief_summary>
	<brief_title>S9717 Tirapazamine Plus Cisplatin Treating Patients With Metastatic , Recurrent , Refractory Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate survival patient metastatic recurrent epithelial squamous adenosquamous carcinoma cervix treat intravenous tirapazamine plus intravenous cisplatin . II . Evaluate unconfirmed complete partial response rate patient , well , nature degree toxicity associate regimen patient population . OUTLINE : Patients receive tirapazamine intravenously 2 hour , follow 1 hour rest , receive cisplatin intravenously 1 hour . Courses repeat every 21 day . Treatment continue 6-10 course absence unacceptable toxic effect disease progression . All patient follow every 6 month 2 year , annually thereafter death . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous adenosquamous carcinoma cervix metastatic , recurrent , refractory Any stage disease treat prior radical surgery and/or definitive radiotherapy locally recur longer amenable surgery radiotherapy OR Metastatic disease amenable surgery radiation therapy Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.5 time upper limit normal Other : No history allergic reaction mannitol Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No prior malignancy except : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer patient currently complete remission Any cancer patient disease free 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor therapy Chemotherapy : Prior chemotherapy ( hydroxyurea , fluorouracil , metronidazole , cisplatin , platinum agent ) allow radiosensitizing agent No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radiotherapy allow less 30 % bone marrow Recovered toxic effect No concurrent radiotherapy Surgery : See Disease Characteristics Prior surgery allow Recovered effect prior surgery Other : No prior systemic therapy disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>